Mimedx (MDXG) EBT (2011 - 2026)
Mimedx recorded quarterly EBT of -$15.3 million in Q1 2026, down 170.34% quarter-over-quarter from $21.8 million in Q4 2025, and down 278.02% year-over-year from $8.6 million in Q1 2025.
Mimedx's EBT history runs 16 years deep, the most recent figure standing at -$15.3 million for Q1 2026.
- In Q1 2026, EBT fell 278.02% year-over-year to -$15.3 million; the TTM figure through Mar 2026 stood at $42.3 million (down 22.34% YoY), while the FY2025 annual figure was $66.3 million, up 15.65% from the prior year.
- EBT came in at -$15.3 million for Q1 2026 at Mimedx, down from $21.8 million in the prior quarter.
- In the past five years, EBT ranged from a high of $23.2 million in Q2 2024 to a low of -$15.3 million in Q1 2026.
- A 5-year average of $7.0 million and a median of $9.9 million in 2022 frame the typical range for EBT.
- On a YoY basis, EBT climbed as much as 10732.97% in 2022 and fell as far as 505.72% in 2022.
- Mimedx's EBT stood at $9.9 million in 2022, then surged by 41.13% to $13.9 million in 2023, then retreated by 19.15% to $11.2 million in 2024, then jumped by 93.75% to $21.8 million in 2025, then sank by 170.34% to -$15.3 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$15.3 million, $21.8 million, and $22.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | -15.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.33 Mn |
| Dec 31, 2025 | 21.80 Mn |
| Sep 30, 2025 | 22.85 Mn |
| Jun 30, 2025 | 13.01 Mn |
| Mar 31, 2025 | 8.61 Mn |
| Dec 31, 2024 | 11.25 Mn |
| Sep 30, 2024 | 11.42 Mn |
| Jun 30, 2024 | 23.22 Mn |
| Mar 31, 2024 | 11.41 Mn |
| Dec 31, 2023 | 13.91 Mn |
| Sep 30, 2023 | 9.43 Mn |
| Jun 30, 2023 | 9.18 Mn |
| Mar 31, 2023 | -1.89 Mn |
| Dec 31, 2022 | 9.86 Mn |
| Sep 30, 2022 | -8.37 Mn |
| Jun 30, 2022 | -10.81 Mn |
| Mar 31, 2022 | -10.43 Mn |
| Dec 31, 2021 | 91,000.00 |
| Sep 30, 2021 | -2.04 Mn |
| Jun 30, 2021 | -1.78 Mn |
| Mar 31, 2021 | -8.32 Mn |
| Dec 31, 2020 | -17.60 Mn |
| Sep 30, 2020 | -19.38 Mn |
| Jun 30, 2020 | -8.44 Mn |
| Mar 31, 2020 | -16.13 Mn |
| Dec 31, 2019 | -7.26 Mn |
| Sep 30, 2019 | 12.07 Mn |
| Jun 30, 2019 | -17.17 Mn |
| Mar 31, 2019 | -13.23 Mn |
| Dec 31, 2018 | -8.73 Mn |
| Sep 30, 2018 | 472,000.00 |
| Jun 30, 2018 | 1.79 Mn |
| Mar 31, 2018 | 3.07 Mn |
| Dec 31, 2017 | 18.91 Mn |
| Sep 30, 2017 | 13.07 Mn |
| Jun 30, 2017 | 7.06 Mn |
| Mar 31, 2017 | 6.04 Mn |
| Dec 31, 2016 | -8.93 Mn |
| Sep 30, 2016 | 4.62 Mn |
| Jun 30, 2016 | 3.45 Mn |
| Mar 31, 2016 | 1.41 Mn |
| Dec 31, 2015 | 7.68 Mn |
| Sep 30, 2015 | 6.71 Mn |
| Jun 30, 2015 | 5.65 Mn |
| Mar 31, 2015 | 4.23 Mn |
| Dec 31, 2014 | 4.64 Mn |
| Sep 30, 2014 | 3.72 Mn |
| Jun 30, 2014 | -400,000.00 |
| Mar 31, 2014 | -912,000.00 |
| Dec 31, 2013 | -1.42 Mn |
| Sep 30, 2013 | -260,418.00 |
| Jun 30, 2013 | -757,389.00 |
| Mar 31, 2013 | -1.57 Mn |
| Dec 31, 2012 | -1.61 Mn |
| Sep 30, 2012 | -4.22 Mn |
| Jun 30, 2012 | -744,069.00 |
| Mar 31, 2012 | -1.09 Mn |
| Dec 31, 2011 | -2.58 Mn |
| Sep 30, 2011 | -1.77 Mn |
| Jun 30, 2011 | -2.50 Mn |
| Mar 31, 2011 | -3.35 Mn |